Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Journal: Expert review of anticancer therapy
Published: March 09, 2022
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.
Journal: Future oncology (London, England)
Published: December 10, 2020
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 21, 2020
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 19, 2019
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: October 04, 2018
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 22, 2018
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: August 07, 2018
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 28, 2018
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Journal: The Lancet. Respiratory medicine
Published: July 25, 2018
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Journal: Clinical lung cancer
Published: December 22, 2017
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Journal: The Lancet. Oncology
Published: May 26, 2017
Last Updated: 09/26/2026